Compare AHCO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | ABUS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.5M | 839.5M |
| IPO Year | 2017 | 2008 |
| Metric | AHCO | ABUS |
|---|---|---|
| Price | $5.63 | $5.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $13.50 | $5.00 |
| AVG Volume (30 Days) | ★ 4.0M | 1.3M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | ★ $3,244,857,000.00 | $14,083,000.00 |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $6.93 | $239.71 |
| P/E Ratio | ★ N/A | $5.68 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $5.21 | $3.49 |
| 52 Week High | $13.43 | $5.38 |
| Indicator | AHCO | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 25.61 | 67.12 |
| Support Level | $5.21 | $4.15 |
| Resistance Level | $10.71 | $5.38 |
| Average True Range (ATR) | 0.39 | 0.19 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 18.96 | 76.17 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.